Phase 3 Trial
Also known as: Phase III trial, Phase 3 study, Pivotal trial, Registration trial
Phase 3 Trial is a large-scale clinical study conducted after Phase 1 and 2 trials to confirm a drug's efficacy, monitor side effects, and compare it to existing treatments. Phase 3 trials typically involve 1,000-3,000 or more participants and provide the pivotal evidence required for FDA approval.
Last updated: January 28, 2026
How Phase 3 Trials Work
Position in Drug Development
| Phase | Focus | Participants |
|---|---|---|
| Phase 1 | Safety, dosing | 20-100 healthy volunteers |
| Phase 2 | Efficacy signals | 100-300 patients |
| Phase 3 | Confirm efficacy | 1,000-3,000+ patients |
| Phase 4 | Post-marketing | General population |
Key Characteristics
- Multi-center (multiple sites, often global)
- Randomized and typically double-blind
- Placebo-controlled or active comparator
- 1-4 years duration
- Expensive ($50-100+ million)
Relevance to Peptides
Landmark Phase 3 Peptide Programs
STEP Trials (Semaglutide/Wegovy)
- STEP 1: 1,961 participants, 68 weeks
- 14.9% weight loss vs 2.4% placebo
- Led directly to FDA approval
SURMOUNT Trials (Tirzepatide/Zepbound)
- SURMOUNT-1: 2,539 participants
- Up to 22.5% weight loss
- Supported obesity indication approval
SURPASS Trials (Tirzepatide/Mounjaro)
- Multiple Phase 3 trials for diabetes
- Head-to-head comparisons with semaglutide
- Demonstrated superior A1C reduction
What Phase 3 Establishes
| Outcome | Example |
|---|---|
| Efficacy confirmation | X% weight loss or A1C reduction |
| Safety profile | Frequency of GI side effects |
| Optimal dosing | Which dose maximizes benefit/risk |
| Comparative effectiveness | How drug compares to alternatives |
| Subgroup effects | Does it work in specific populations |
Phase 3 Trial Design Elements
Endpoints
- Primary endpoint: Main outcome (weight loss, A1C change)
- Secondary endpoints: Additional measures
- Safety endpoints: Adverse events tracked
Analysis Populations
- Intent-to-treat (all randomized)
- Per-protocol (completed as designed)
- Safety population (received any treatment)
After Phase 3
Successful Phase 3 results lead to:
- New Drug Application (NDA) submission
- FDA review (typically 10-12 months)
- Advisory committee review (sometimes)
- Approval decision
- Post-marketing (Phase 4) requirements
Frequently Asked Questions
Why do Phase 3 trials take so long?
Large participant numbers require extensive recruitment. Outcomes like weight maintenance or cardiovascular events require long follow-up. Multiple sites and countries add logistical complexity. The extensive data collection and monitoring ensure reliable results.
Can a drug fail in Phase 3 after succeeding in Phase 2?
Yes, this happens frequently. Phase 2 involves smaller, selected populations. Phase 3’s larger, diverse population may reveal the drug doesn’t work as well broadly, has unexpected side effects, or doesn’t outperform existing treatments.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.